Crowdfunding Campaign Targets the Underfunded Science of Ovarian Aging

Ovarian aging has long been treated as a reproductive footnote, but a growing body of research is repositioning it as a central driver of female healthspan with consequences spanning the cardiovascular, metabolic, skeletal, neurological, and immune systems. The Longevity Science Foundation's new crowdfunding campaign, 'Invested in Her,' aims to accelerate this scientific reckoning by raising $250,000 for targeted research — with a $25,000 matching grant from LongeVC unlocked upon reaching the goal.

The campaign is structured around three pillars. The first focuses on measurement, developing a so-called 'menopause clock' — molecular sensors capable of tracking the biological progression of ovarian aging with precision. The second pillar addresses the underlying biology of how ovarian decline triggers systemic changes across organ systems. The third targets interventions that could modify ovarian aging trajectories and potentially delay or reduce downstream health risks.

The scientific rationale is compelling. Women outlive men on average but spend more years in poor health. The menopausal transition is associated with sharp increases in cardiometabolic risk, neurodegeneration, and bone loss. Osteoporosis prevalence is roughly five times higher in women than men, and hip fracture mortality is comparable to that of breast cancer — statistics that reframe menopause as a major public health concern rather than a lifestyle inconvenience.

Geroscience increasingly views menopause not as an endpoint but as a measurable, modifiable inflection point — one where timely intervention could reshape long-term health trajectories. The ovary, researchers suggest, functions less like spent reproductive hardware and more like a systemic regulator whose decline sends ripple effects throughout the body.

While $250,000 is modest in the context of large-scale biomedical funding, the campaign's advocates argue its impact extends beyond dollars — shifting scientific priorities, sharpening research language, and making it harder for funders and policymakers to continue treating female aging biology as peripheral. Whether it catalyzes broader institutional investment remains to be seen.